Answers are grounded in this paper and cite their sources.
Prospective observational study shows improved autonomic function in type 2 diabetes patients with cardiac autonomic neuropathy, suggesting alpha lipoic acid's potential benefits.
One of the major side effects of diabetes mellitus (DM) that raises the rates of morbidity and death is diabetic cardiovascular autonomic neuropathy (CAN). As an antioxidant, alpha lipoic acid shows promise in lowering autonomic neuropathy. 138 participants with type 2 DM participated in the prospective observational research. Autonomic function, biochemical markers, and baseline demographics were measured. Patients receiving anti-diabetic medicine and oral dose of 200 mg of alpha lipoic acid for complications were observed for three months. Prior to and following the three-month period, the autonomic nerve system index (ANS) score was assessed. The ANS index score significantly decreased, and the neuropathy was found to have improved. There was statistical significance in the results. The study's conclusions demonstrated alpha lipoic acid's possible advantages in CAN management.
No takes yet. Share an insight, caveat, or question.
Geetha et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: